JP2018520685A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018520685A5 JP2018520685A5 JP2018502133A JP2018502133A JP2018520685A5 JP 2018520685 A5 JP2018520685 A5 JP 2018520685A5 JP 2018502133 A JP2018502133 A JP 2018502133A JP 2018502133 A JP2018502133 A JP 2018502133A JP 2018520685 A5 JP2018520685 A5 JP 2018520685A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- seq
- nos
- strand
- monomers
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 58
- 239000000178 monomer Substances 0.000 claims 23
- 125000003729 nucleotide group Chemical group 0.000 claims 9
- 108020004707 nucleic acids Proteins 0.000 claims 5
- 150000007523 nucleic acids Chemical class 0.000 claims 5
- 102000039446 nucleic acids Human genes 0.000 claims 5
- 239000002773 nucleotide Substances 0.000 claims 5
- 150000002632 lipids Chemical class 0.000 claims 3
- 102000003886 Glycoproteins Human genes 0.000 claims 2
- 108090000288 Glycoproteins Proteins 0.000 claims 2
- MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 claims 2
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 claims 2
- 230000000692 anti-sense effect Effects 0.000 claims 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 230000009368 gene silencing by RNA Effects 0.000 claims 2
- 208000002672 hepatitis B Diseases 0.000 claims 2
- 239000002105 nanoparticle Substances 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 238000006467 substitution reaction Methods 0.000 claims 2
- IQFYYKKMVGJFEH-GJMOJQLCSA-N 1-[(2r,4r,5s)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@@H](CO)[C@H](O)C1 IQFYYKKMVGJFEH-GJMOJQLCSA-N 0.000 claims 1
- MSWZFWKMSRAUBD-GASJEMHNSA-N 2-amino-2-deoxy-D-galactopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O MSWZFWKMSRAUBD-GASJEMHNSA-N 0.000 claims 1
- 208000035657 Abasia Diseases 0.000 claims 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 1
- 241000700721 Hepatitis B virus Species 0.000 claims 1
- OVRNDRQMDRJTHS-CBQIKETKSA-N N-Acetyl-D-Galactosamine Chemical compound CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-CBQIKETKSA-N 0.000 claims 1
- OVRNDRQMDRJTHS-KEWYIRBNSA-N N-acetyl-D-galactosamine Chemical compound CC(=O)N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-KEWYIRBNSA-N 0.000 claims 1
- 108020004459 Small interfering RNA Proteins 0.000 claims 1
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical class O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 claims 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 claims 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 claims 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 claims 1
- 235000012000 cholesterol Nutrition 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229910052731 fluorine Inorganic materials 0.000 claims 1
- 239000011737 fluorine Substances 0.000 claims 1
- 229930182830 galactose Natural products 0.000 claims 1
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 claims 1
- 230000012010 growth Effects 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 239000002502 liposome Substances 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000035800 maturation Effects 0.000 claims 1
- 238000013160 medical therapy Methods 0.000 claims 1
- 230000008685 targeting Effects 0.000 claims 1
- 229960005311 telbivudine Drugs 0.000 claims 1
- XXYIANZGUOSQHY-XLPZGREQSA-N thymidine 3'-monophosphate Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](OP(O)(O)=O)C1 XXYIANZGUOSQHY-XLPZGREQSA-N 0.000 claims 1
- 230000029812 viral genome replication Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562193997P | 2015-07-17 | 2015-07-17 | |
| US62/193,997 | 2015-07-17 | ||
| PCT/US2016/042694 WO2017015175A1 (en) | 2015-07-17 | 2016-07-17 | Compositions and agents against hepatitis b virus and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018520685A JP2018520685A (ja) | 2018-08-02 |
| JP2018520685A5 true JP2018520685A5 (enExample) | 2019-03-28 |
| JP6924744B2 JP6924744B2 (ja) | 2021-08-25 |
Family
ID=57775056
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018502133A Active JP6924744B2 (ja) | 2015-07-17 | 2016-07-17 | Ｂ型肝炎ウイルスに対する組成物および薬剤ならびにその使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20170016000A1 (enExample) |
| EP (1) | EP3325097B1 (enExample) |
| JP (1) | JP6924744B2 (enExample) |
| CN (1) | CN108136206B (enExample) |
| AU (1) | AU2016296592B2 (enExample) |
| CA (1) | CA2996722A1 (enExample) |
| TW (1) | TWI761311B (enExample) |
| WO (1) | WO2017015175A1 (enExample) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI2726613T1 (sl) | 2011-06-30 | 2018-10-30 | Arrowhead Pharmaceuticals, Inc. | Sestavki in postopki za zaviranje izražanja gena virusa hepatitisa B |
| CN108271387B (zh) | 2015-08-07 | 2023-06-27 | 箭头药业股份有限公司 | 乙型肝炎病毒感染的RNAi疗法 |
| MA45496A (fr) | 2016-06-17 | 2019-04-24 | Hoffmann La Roche | Molécules d'acide nucléique pour la réduction de l'arnm de padd5 ou pad7 pour le traitement d'une infection par l'hépatite b |
| JOP20170161A1 (ar) | 2016-08-04 | 2019-01-30 | Arrowhead Pharmaceuticals Inc | عوامل RNAi للعدوى بفيروس التهاب الكبد ب |
| KR102585898B1 (ko) | 2017-10-16 | 2023-10-10 | 에프. 호프만-라 로슈 아게 | B형 간염 감염을 치료하기 위한 PAPD5 및 PAPD7 mRNA의 감소용 핵산 분자 |
| US12083142B2 (en) | 2017-12-01 | 2024-09-10 | Suzhou Ribo Life Science Co., Ltd. | Nucleic acid, composition and conjugate comprising the same, and preparation method and use thereof |
| KR102756073B1 (ko) | 2017-12-01 | 2025-01-20 | 쑤저우 리보 라이프 사이언스 컴퍼니, 리미티드 | 이중-가닥 올리고뉴클레오티드, 조성물 및 이중-가닥 올리고뉴클레오티드를 포함하는 접합체, 그의 제조 방법 및 그의 용도 |
| WO2019105419A1 (zh) | 2017-12-01 | 2019-06-06 | 苏州瑞博生物技术有限公司 | 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途 |
| WO2019105435A1 (zh) * | 2017-12-01 | 2019-06-06 | 苏州瑞博生物技术有限公司 | 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途 |
| JP7261494B2 (ja) | 2017-12-01 | 2023-04-20 | スーチョウ リボ ライフ サイエンス カンパニー、リミテッド | 核酸、当該核酸を含む組成物及び複合体ならびに調製方法と使用 |
| HRP20250408T1 (hr) | 2017-12-29 | 2025-06-06 | Suzhou Ribo Life Science Co., Ltd. | Kojugati i njihova priprema i uporaba |
| EP3775208A1 (en) | 2018-04-05 | 2021-02-17 | F. Hoffmann-La Roche AG | Use of fubp1 inhibitors for treating hepatitis b virus infection |
| JP7384833B2 (ja) | 2018-05-16 | 2023-11-21 | アルニラム・ファーマシューティカルズ・インコーポレーテッド | オフターゲット効果が低下した修飾ｒｎａ剤 |
| KR102273071B1 (ko) * | 2018-06-12 | 2021-07-05 | 주식회사 에이엠사이언스 | B형 간염 예방 또는 치료용 조성물 |
| WO2019240504A1 (en) * | 2018-06-12 | 2019-12-19 | Am Sciences Co., Ltd. | Modified oligonucleotides for inhibition of target gene expression |
| AU2019297391B2 (en) | 2018-07-03 | 2023-01-12 | F. Hoffmann-La Roche Ag | Oligonucleotides for modulating Tau expression |
| MX2021000404A (es) | 2018-07-13 | 2021-03-25 | Hoffmann La Roche | Oligonucleotidos para modular la expresion de rtel1. |
| US11918600B2 (en) | 2018-08-21 | 2024-03-05 | Suzhou Ribo Life Science Co., Ltd. | Nucleic acid, pharmaceutical composition and conjugate containing nucleic acid, and use thereof |
| CN111655297A (zh) | 2018-09-30 | 2020-09-11 | 苏州瑞博生物技术有限公司 | 一种siRNA缀合物及其制备方法和用途 |
| CN110218728A (zh) * | 2019-06-28 | 2019-09-10 | 厦门甘宝利生物医药有限公司 | 一种新化合物及其应用 |
| WO2021107097A1 (ja) * | 2019-11-28 | 2021-06-03 | 株式会社ボナック | Ｂ型肝炎治療用核酸分子 |
| WO2021122910A1 (en) | 2019-12-19 | 2021-06-24 | F. Hoffmann-La Roche Ag | Use of sbds inhibitors for treating hepatitis b virus infection |
| WO2021122869A1 (en) | 2019-12-19 | 2021-06-24 | F. Hoffmann-La Roche Ag | Use of scamp3 inhibitors for treating hepatitis b virus infection |
| WO2021122735A1 (en) | 2019-12-19 | 2021-06-24 | F. Hoffmann-La Roche Ag | Use of sept9 inhibitors for treating hepatitis b virus infection |
| WO2021122921A1 (en) | 2019-12-19 | 2021-06-24 | F. Hoffmann-La Roche Ag | Use of cops3 inhibitors for treating hepatitis b virus infection |
| WO2021122993A1 (en) | 2019-12-19 | 2021-06-24 | F. Hoffmann-La Roche Ag | Use of saraf inhibitors for treating hepatitis b virus infection |
| US20220056451A1 (en) * | 2020-07-27 | 2022-02-24 | Aligos Therapeutics, Inc. | Hbv binding oligonucleotides and methods of use |
| EP4200419A2 (en) | 2020-08-21 | 2023-06-28 | F. Hoffmann-La Roche AG | Use of a1cf inhibitors for treating hepatitis b virus infection |
| IL302530A (en) * | 2020-11-06 | 2023-07-01 | Arbutus Biopharma Corp | Targeted conjugates involving modified siRNA |
| CN116916935A (zh) * | 2020-12-18 | 2023-10-20 | 奥利克斯医药有限公司 | 抑制乙型肝炎病毒表达的RNAi制剂以及其用途 |
| WO2022147304A1 (en) * | 2020-12-31 | 2022-07-07 | Arcturus Therapeutics, Inc. | Compositions and methods for treating metabolic disorders |
| CN114767704B (zh) * | 2021-01-21 | 2024-06-14 | 圣诺制药公司 | 一种能够靶向乙型肝炎病毒的药物构造及药物组合物 |
| TW202246500A (zh) | 2021-02-02 | 2022-12-01 | 瑞士商赫孚孟拉羅股份公司 | 用於抑制 ｒｔｅｌ１ 表現之增強型寡核苷酸 |
| WO2023111210A1 (en) | 2021-12-17 | 2023-06-22 | F. Hoffmann-La Roche Ag | Combination of oligonucleotides for modulating rtel1 and fubp1 |
| CN115267193B (zh) * | 2022-09-20 | 2022-12-27 | 北京大学 | 用于判断生物样本中HBsAg来源的方法及系统和用途 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030206887A1 (en) * | 1992-05-14 | 2003-11-06 | David Morrissey | RNA interference mediated inhibition of hepatitis B virus (HBV) using short interfering nucleic acid (siNA) |
| US9181551B2 (en) | 2002-02-20 | 2015-11-10 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
| DE60322884D1 (de) | 2002-05-10 | 2008-09-25 | Tekmira Pharmaceuticals Corp | Pathogene impstoffe und verfahren zur deren verwendung |
| US20070027099A1 (en) * | 2003-05-19 | 2007-02-01 | Lin Marie C | Gene therapy of HBV infection via adeno-associated viral vector mediated long term expression of small hairpin RNA (shRNA) |
| US8575327B2 (en) | 2003-06-12 | 2013-11-05 | Alnylam Pharmaceuticals, Inc. | Conserved HBV and HCV sequences useful for gene silencing |
| CA2528510C (en) | 2003-06-12 | 2019-06-04 | Nucleonics, Inc. | Conserved hbv and hcv sequences useful for gene silencing |
| CN1981033A (zh) | 2004-05-19 | 2007-06-13 | 墨尔本保健公司 | 乙型肝炎的治疗、预防和诊断试剂 |
| EP1796732B1 (en) | 2004-10-01 | 2013-10-30 | Novartis Vaccines and Diagnostics, Inc. | Modified small interfering rna molecules and methods of use |
| US8765704B1 (en) | 2008-02-28 | 2014-07-01 | Novartis Ag | Modified small interfering RNA molecules and methods of use |
| KR20100060018A (ko) | 2005-03-09 | 2010-06-04 | 재단법인 목암생명공학연구소 | 작은 간섭 ｒｎａ 및 이를 포함하는 ｂ형 간염 바이러스 치료용 약학 조성물 |
| CA2683063A1 (en) | 2007-04-09 | 2008-10-16 | Chimeros, Inc. | Self-assembling nanoparticle drug delivery system |
| CN104480112B (zh) | 2007-05-22 | 2018-06-12 | 阿克丘勒斯治疗公司 | 用于治疗的una寡聚体 |
| KR20100069679A (ko) | 2007-09-17 | 2010-06-24 | 재단법인 목암생명공학연구소 | ＨＢＶ 또는 ＨＣＶ의 유전자 발현을 하향 조절하는 ｓｉＲＮＡ의 혈청 안정성 향상 및 면역 반응 저감 방법 |
| WO2009106999A2 (en) | 2008-02-28 | 2009-09-03 | Deutsches Krebsforschungszentrum, Stiftung Des Öffentlichen Rechts | Hollow nanoparticles and uses thereof |
| US20100015708A1 (en) * | 2008-06-18 | 2010-01-21 | Mdrna, Inc. | Ribonucleic acids with non-standard bases and uses thereof |
| AU2009322290B2 (en) * | 2008-12-03 | 2016-06-16 | Arcturus Therapeutics, Inc. | Una oligomer structures for therapeutic agents |
| EP2512491B1 (en) | 2009-10-16 | 2017-10-11 | Glaxo Group Limited | Hbv antisense inhibitors |
| EP4079856A1 (en) | 2010-08-17 | 2022-10-26 | Sirna Therapeutics, Inc. | Rna interference mediated inhibition of hepatitis b virus (hbv) gene expression using short interfering nucleic acid (sina) |
| CR20190207A (es) | 2011-04-21 | 2019-06-26 | Ionis Pharmaceuticals Inc | MODULACIÓN DE LA EXPRESIÓN DEL VIRUS DE LA HEPATITIS B (VHB) (Divisional 2013-0551) |
| SI2726613T1 (sl) * | 2011-06-30 | 2018-10-30 | Arrowhead Pharmaceuticals, Inc. | Sestavki in postopki za zaviranje izražanja gena virusa hepatitisa B |
| WO2013061295A1 (en) | 2011-10-28 | 2013-05-02 | University Of The Witwatersrand, Johannesburg | Inhibition of viral gene expression |
| WO2013159109A1 (en) | 2012-04-20 | 2013-10-24 | Isis Pharmaceuticals, Inc. | Modulation of hepatitis b virus (hbv) expression |
| BR112015003985A2 (pt) | 2012-08-30 | 2017-08-08 | Replicor Inc | métodos para tratamento de infecções de hepatite b e hepatite d |
| CN105103603A (zh) | 2012-12-05 | 2015-11-25 | 诺基亚通信公司 | 用于流量导向的方法和网络元件 |
| JP6546161B2 (ja) | 2013-10-04 | 2019-07-17 | ノバルティス アーゲー | Ｂ型肝炎ウイルスを治療するための有機化合物 |
| JP6486955B2 (ja) | 2013-11-18 | 2019-03-20 | アークトゥルス セラピューティクス， インコーポレイテッド | Ｒｎａ送達のためのイオン化可能なカチオン性脂質 |
| GB201408623D0 (en) | 2014-05-15 | 2014-07-02 | Santaris Pharma As | Oligomers and oligomer conjugates |
| US20170145424A1 (en) | 2014-06-06 | 2017-05-25 | Ionis Pharmaceuticals, Inc. | Compositions and methods for enhanced intestinal absorption of conjugated oligomeric compounds |
| CN107208095B (zh) | 2014-10-02 | 2021-11-16 | 阿布特斯生物制药公司 | 用于使乙型肝炎病毒基因表达沉默的组合物和方法 |
-
2016
- 2016-07-17 US US15/212,279 patent/US20170016000A1/en not_active Abandoned
- 2016-07-17 AU AU2016296592A patent/AU2016296592B2/en active Active
- 2016-07-17 CA CA2996722A patent/CA2996722A1/en active Pending
- 2016-07-17 JP JP2018502133A patent/JP6924744B2/ja active Active
- 2016-07-17 EP EP16828341.4A patent/EP3325097B1/en active Active
- 2016-07-17 WO PCT/US2016/042694 patent/WO2017015175A1/en not_active Ceased
- 2016-07-17 CN CN201680053632.1A patent/CN108136206B/zh active Active
- 2016-09-10 TW TW105129484A patent/TWI761311B/zh active
-
2018
- 2018-08-30 US US16/117,994 patent/US10961535B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018520685A5 (enExample) | ||
| CN108136206B (zh) | 抗乙型肝炎病毒的组合物和药剂及其用途 | |
| JP7442574B2 (ja) | Ｌｐａの遺伝子発現の阻害のための組成物及び方法 | |
| JP6752151B2 (ja) | 遺伝子サイレンシングにおいて低下したｏｆｆ−ｔａｒｇｅｔ効果を有するｕｎａオリゴマー | |
| JP2018529732A5 (enExample) | ||
| US8936910B2 (en) | Method for selective oligonucleotide modification | |
| US10538763B2 (en) | Compounds and methods for modulation of DUX4 | |
| JP2019504112A5 (enExample) | ||
| TW202018081A (zh) | 用於B型肝炎病毒感染之RNAi藥劑 | |
| JP2018519835A5 (enExample) | ||
| JP2017538679A5 (enExample) | ||
| JP2018530529A5 (enExample) | ||
| JP2019533472A5 (enExample) | ||
| CN115516092A (zh) | 血管生成素样3(ANGPTL3)的siRNA及其用途 | |
| JP2016520312A5 (enExample) | ||
| CN113507920A (zh) | 用于乙型肝炎病毒感染的RNAi剂 | |
| JP2017532038A5 (enExample) | ||
| TW201408309A (zh) | 用於治療ｂ型肝炎及ｄ型肝炎感染之方法 | |
| RU2020135289A (ru) | Применение ингибиторов fubp1 для лечения инфекции вирусом гепатита в | |
| RU2020115761A (ru) | МОЛЕКУЛЫ НУКЛЕИНОВЫХ КИСЛОТ ДЛЯ УМЕНЬШЕНИЯ УРОВНЯ мРНК PAPD5 ИЛИ PAPD7 ДЛЯ ЛЕЧЕНИЯ ИНФЕКЦИОННОГО ГЕПАТИТА В | |
| WO2012174224A2 (en) | Methods for administering nucleic acid-based therapeutics | |
| KR20150006742A (ko) | 간암 연관 유전자 특이적 siRNA, 그러한 siRNA를 포함하는 이중나선 올리고 RNA 구조체 및 이를 포함하는 암 예방 또는 치료용 조성물 | |
| RU2014121304A (ru) | Ингибирование экспрессии вирусных генов | |
| TW202237189A (zh) | 具有增強之肝靶向的ｓ抗原運輸抑制寡核苷酸聚合物之接合物 | |
| CN115702006A (zh) | 缀合基团及其缀合物 |